Skip to main content
Equibles
HRMY logo

HRMY · Harmony Biosciences Holdings, Inc. · Metrics

Track HRMY — free

Use HRMY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HRMY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$33.76 -0.04 (-0.12%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.98B
Shares
58.72M
Volume · Nov 13 844.92K Avg daily vol (3M) 999.19K

HRMY metrics

104 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$33.76
Market cap
$1.98B

Price action

23 metrics
Price change (1W)
+2.0%
Price change (30D)
-11.8%
Price change (3M)
-11.4%
Price change (6M)
+12.2%
Price change (YTD)
-9.8%
Price change (1Y)
-1.5%
Trailing year
Price change (5Y)
-20.6%
52-week high
$42.86
52-week low
$26.54
Change from 52-week high
-21.2%
Change from 52-week low
+27.2%
Annualized volatility
40.6%
Annualized volatility (3M)
36.4%
Implied volatility (30D)
81.4%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.7
RSI (14D)
36.4
Price vs SMA 50
-12.6%
Price vs SMA 200
-2.4%
Avg volume (3M)
999,188
Relative volume
0.9
Average dollar volume
$38.67M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
58.72M

Valuation

12 metrics
P / E (TTM)
11.2
Trailing earnings · reciprocal yield 8.9%
PEG ratio
—
EV / revenue
1.4×
reciprocal yield 72.7%
EV / EBITDA
5.9×
reciprocal yield 16.9%
EV / EBIT
6.2×
reciprocal yield 16.1%
P / sales
2.0×
reciprocal yield 49.9%
P / book
1.8
reciprocal yield 54.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
6.1
reciprocal yield 16.3%
Earnings yield
9.0%

Historical valuation

8 metrics
P / E historical average (3Y)
13.3×
reciprocal yield 7.5%
P / E historical average (5Y)
29.4×
reciprocal yield 3.4%
EV / revenue historical average (3Y)
2.1×
reciprocal yield 47.7%
EV / revenue historical average (5Y)
3.9×
reciprocal yield 25.8%
EV / EBIT historical average (3Y)
7.8×
reciprocal yield 12.8%
EV / EBIT historical average (5Y)
14.0×
reciprocal yield 7.1%
EV / EBITDA historical average (3Y)
8.8×
reciprocal yield 11.3%
EV / EBITDA historical average (5Y)
13.3×
reciprocal yield 7.5%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-04

Profitability

9 metrics
Gross margin
74.0%
Operating margin
22.2%
Trailing 12 months
Net margin
18.1%
Gross profit (TTM)
$732.42M
Operating profit (TTM)
$219.36M
Net income (TTM)
$178.60M
Trailing 12 months
Diluted EPS (TTM)
$3.02
FCF margin
—
Effective tax rate
23.3%

Per share

11 metrics
Revenue per diluted share (TTM)
$16.78
Gross profit per diluted share (TTM)
$12.43
Operating profit per diluted share (TTM)
$3.72
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$3.03
Operating cash flow per diluted share (TTM)
$5.49
Free cash flow per diluted share (TTM)
$5.94
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$4.03
Stock compensation per diluted share (TTM)
$0.64
Book value per share
$15.07

Growth

11 metrics
Revenue growth YoY
+12.3%
Year over year
Net income growth YoY
-5.2%
Revenue (TTM)
$989.36M
Trailing 12 months
EPS growth YoY
-6.9%
Shares change YoY
+1.6%
Year over year · more shares
Revenue CAGR (3Y)
+25.6%
Revenue CAGR (5Y)
+40.3%
EPS CAGR (3Y)
-3.0%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+34.1%
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
16.7%
Return on assets
12.1%
Debt / equity
0.1
Current ratio
3.4
EBITDA (TTM)
$249.51M
Free cash flow (TTM)
—
Quick ratio
3.4
Interest coverage
17.0
Net debt / EBITDA
-2.0
Return on invested capital
37.4%
Trailing 12 months
Net cash
$622.03M
Latest balance sheet
Cash & equivalents
$647.10M
Total assets
$1.48B
Total debt
$149.10M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$323.04M
Capital expenditures (TTM)
$310,000
R&D (TTM)
$237.57M
SG&A (TTM)
—
Stock compensation (TTM)
$37.97M
R&D / revenue
24.0%
Stock compensation / revenue
3.8%

Ownership (13F)

9 metrics
13F filers
327
13F filer change QoQ
+16
Institutional ownership
92.9%
Conviction holders (share of 13F filers)
0.6%
Crowding (high-turnover and private-fund holders)
30.7%
Private-fund adviser ownership
28.7%
Active holders' share change QoQ
-2.7%
Holder tenure
13.3
Price vs estimated holder cost
+5.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
23.2%

Short interest

3 metrics
Short interest
11.3%
Latest settlement · 5.6 days to cover
Days to cover
5.6d
Short-squeeze score
70 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$3.11M
Insider-sentiment score
25 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1802665 CUSIP 413197104 13F (30d) 283 filings 265 filers Visit website Investor relations